Article: Nicotinamide Riboside Protects Kidneys after Heart Attack: Preclinical Findings

PrevNext
Cardiovascular Disease Cardiovascular Health Kidney Disease Kidney Health Preclinical

Nicotinamide Riboside Protects Kidneys after Heart Attack: Preclinical Findings

Synopsis

Cardiorenal syndrome type 1 occurs when acute kidney injury (AKI) develops after sudden heart problems like a heart attack (MI), increasing the risk of death. This study tested whether nicotinamide riboside (NR), a precursor of NAD+, could help protect the kidneys after MI. In mice, MI reduced heart NAD+ levels, but NR treatment for 4–7 days did not improve heart function. However, NR improved kidney function, reduced cell death, and protected kidney tissue, likely by increasing NAD+ levels through NAMPT in kidney cells, especially in the distal tubules. These results suggest that NR may help prevent kidney damage after a heart attack.

Journal

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Share

Read more

Liver Disease

Nicotinamide Riboside Protects Liver Immune Cells from Alcohol-Induced Damage: Preclinical Findings

SynopsisAlcohol-related liver disease (ALD) is linked to mitochondrial dysfunction and impaired energy metabolism. This study examined how ethanol damages Kupffer cells, the liver's resident immune...

Read more
Diabetes

Nicotinamide Riboside Protects Gut Nerve Health and Improves Gastrointestinal Transit in Diabetes: Preclinical Findings

SynopsisDiabetes causes systemic oxidative stress that often leads to nerve damage in the enteric nervous system, impairing gut motility and causing symptoms such as constipation or diarrhea. Using...

Read more